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CHAPTER I 
INTRODUCTION 
The purpose of this report is to assemble the known information on 
hexahomoserine. Hexahomoserine is an amino acid notfound in nature., but 
closely related in structure to the essential amino acid lysine. Many 
studies have been made to determine if hexahomoserine could be used as a 
substitute for lysine in the diet of various organisms. Contrary to ex-
pected results., hexahomoserine has been found to be a lysine inhibitor. 
This compound is of particular interest because it has since been iden-
tified as the toxic component of deaminized casein. 
Other names found in the literature for hexahomoserine are O',-amino-
~-hydroxycaproic acid., 2-amino-6-hydroxycaproic acid, O',-amino-~-hydroxy-




As early as 1934, an unidentified anemia-causing factor was discov-
ered in deaminated casein by Hogan and Ritchie (21). The factor was be-
lieved to be the deficiency of one or more essential amino acids or the 
presence of a toxic agent. Albino rats which weighed approximately 75 
gr?:ms were used as the experimental animals. (Smaller animals were less 
resistant to the unsatisfactory diet.) The animals were divided into 
groups and placed on different diets which varied in the amount and kind 
of protein given. The proteins used were deaminized casein, gelatin, 
gliadin and casein. The animals on diets that consisted of deaminized 
casein as the only protein source declined in weight from the beginning. 
They developed a severe anemia which was confirmed by the presence of 
abnormally low numbers of red blood cells. None of the animals survived 
longer than 40 days. The workers believed the anemia was due to a defi-
ciency of lysine. They then fed rats a diet which consisted of deaminized 
casein and gelatin. (Gelatin was known to contain 5.9 per cent lysine.) 
The animals survived for a longer period of time on this diet, but soon 
died and there were no significant weight gains among the animals. The 
lysine in the gelatin was credited with the improvement. Animals fed a 
diet of deaminized casein, gelatin and gliadin showed no improvement over 
the previous diet. Casein alone proved to be a sufficient diet. Gliadin 
and casein used together were no more satisfactory than casein alone. A 
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combination of gelatin and gliadin proved to be an adequate source of 
protein. Other combinations of gelatin, gliadin and casein were unsat-
isfactory. It was found that when the diet consisted of equal amounts of 
deaminized casein and casein, the animals did not develop anemia and con-
tinued to grow in a normal manner. 
In further studies on the anemia, Hogan, Guerrant and Ritchie (19) 
found that anemic, albino rats on a diet of 10 per cent deaminized casein 
required an addition to the diet of approximately 5 per cent casein to 
prevent the anemia. The anemia can be produced by the addition of a min-
imal amount of deaminized casein, which lies between 5 and 10 per cent of 
the ration. Substances found ineffective against the anemia at levels 
from 100 to 400 mg. of dry matter were milk, egg yolk, wheat germ oil, 
ventriculin, ·muscle, liver and stomach. Protection against the anemia 
caused by deaminized casein was conferred by the addition of dry yeast in 
the amount of 18 per cent to the diet. The attempt to recover the active 
agent of yeast with water was unsuccessful. Autoclaving casein and yeast 
inhibits their ability to overcome the anemia produced by deaminized 
casein. The active agent of deaminized casein could be recovered in the 
hydrolyzate when it was hydrolyzed with 25 per cent sulfuric acid at at-
mospheric pressure. The antianemic agent in casein could likewise be re-
covered. 
Smith and StohJ:man (45) working with the anemia produced by deami-
nized casein confirmed the work of Hogan and Ritchie (21). They found 
that when deaminized casein was fed at a level of 10 per cent in the diet 
of a white rat., a characteristic macrocytic megaloblastic anemia with 
many Howell-Jollie bodies was produced. Good quality protein added to 
the diet would not prevent the anemia, but would lessen its severity. 
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They found that deaminized casein boiled with alcoholic sodium hydroxide 
or reprecipitated from aqueous alkaline solution lacked the anemia-pro-
ducing factor for the most part. When animals were injected intraperito-
neally with the alcohol soluble fraction of a hydrochloric acid hydroly-
zate of deaminized casein., they developed the anemia. This proved that 
the anemia is an intoxication and not a deficiency disease. 
In studies by Hogan., Powell and Guerrant (20) lysine appeared to be 
the amino acid responsible for recovery when eithe.r casein hydrolyzate or 
that copper-salt fraction which is soluble in water and insoluble in 
methyl alcohol was administered to anemic rats. It was also shown by 
biological methods that the only essential amino acid missing in signifi-
cant amount from deaminized casein is lysine. They showed that lysine 
added in the amount of approximately 2 per cent was sufficient to permit 
recovery from the anemia. 
CHAPTER III 
PROOF OF STRUCTURE AND CHEMICAL PROPERTIES 
. a-Animo-€-hydroxycaproic acid was synthesized by Gaudry (8, 9) in 
1947. This was the first time that the.compound had been synthesized in 
such a way as to establish its chemical structure. Acid hydrolysis of 
dihydropyran (I) gives t'-hydroxyvaleraldehyde (IIL to which is applied 
the Bucherer modification of the Strecker synthesis for a-amino acids. 
The aqueous solution is used to prepare the corresponding cyanohydrin, 
a,t-dihydroxycaproic nitrile (III). This compound yields 5-8-hydroxybutyl-
hydantoin (IV) which when hydrolyzed under pressure with barium hydroxide 
gives a 95 per cent yield of D,L-a-amino-£-hydroxycaproic acid (v). The 
name proposed for the compound by Gaudry is "hexahomoserine" because it 
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The melting point varies between 245° and 248°c and 260° and 262°c with 
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gas evolution varying according to the rate of heating. The nitrogen 
content calculated for C6 H1303 N is 9.52 per cent. The amount of nitrogen 
found (Kjeldahl) is 14.98 per cent. It was suspected that hexahomoserine 
is the same as the compound in deaminized casein which produced anemia in 
rats. 
The optical rotation of 99.9% optically pure L- and D-isomers and 
their susceptibility to Crotalus adamanteus L-amino acid oxidase and hog 
kidney D-amino acid oxidase as determined by Greenstein, Birnbaum and 
Otey (17) and Greenstein (16) is as follows: 
L-Isomers D-Isomers 
LMJ0 in Oxidation Oxidation by by L-amino D-amino acid 
H20 5N HCl Glacial acid oxidase 
Acetic oxidase 
Acid 
+5 .9 +54.9 +57.4 201 3.2 
.{;M~ is molar rotation which is .{;aJ0 (rotation) x 147.l ~ 100. The 
11D11 stands for the sodium line which is 589mµ. The 147 .1 is the molecular 
weight of hexahomoserine. The rates for oxidation by L- and D-amino acid 
oxidase is expressed in terms of micromoles of oxygen consumed per mg. of 
nitrogen. 
Berlinquet and Gaudry (4) established the optical rotation for a 2 
per cent solution of the D- and L-isomers in 6 N HCl obtained by the asym-
metric hydrolysis of chloroacetyl-D,L-a-amino-€-hydroxy-n-caproic a~id 
by an enzyme preparation from hog kidney. The value for L-a-amino-E-
hydroxy-n-caproic acid is .[;aJD27= +23.7° and for D-a-amino-€-hydroxy-n-
caproic acid is .[;aJ;3 =-23.2°. 
Other rotary dispersion data for the L-isomer of hexahomoserine as 
determined by Otey et al. (37) is as follows: 






The optical rotations were determined with a photoelectric polarimeter. 
The values in the table refer to the Dor 589 mµ line of sodium. The 
values of A were determined from the dispersion data by the method of 
0 
least squares. 
In studying lysine biosynthesis in Neurospora Schweet, Holden and 
Lowy (44) found the chromatographic mobility of hexahomoserine to be 
0.42 in butanol-acetic acid, 0.66 in pyridine-water and 0.74 in phenol-
water. The values are given as RF. 
Kroegel et al. (22) established the absorption spectrum in the 
infrared in the 2 to 8µ region to be as follows: 
2 - 5µ 5 - 7µ 











w=weak intensity, s=sharp band, M=medium intensity, 
B=broad band and S=strong intensity. 
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Dent (7) found that hexahomoserine (ninhydrin reactant) is detectable 
in amounts of 10 µg on phenol= 1collidine 1 filter-paper chromatograms. The 
characteristic spot gives a purple color. The hydrolyzate of deaminated 
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casein gives a similar spot in the exact position of the hexahomoserine 
spot. These results tend to prove that the anemia-producing factor in 
deaminated casein and hexahomoserine are the same substance. 
A compound prepared by MacDonald and Tullock (23) from hexahomoserine 
is €-acetoxy-D)L-CX-aminocaproic acid HCl. 
CHAPTER T:iJ 
ENZYME AND BACTERIAL STUDIES 
Various enzyme studies have been conducted on hexahomoserine with 
limited resultso L-amino oxidase prepared from the hepato-pancreas of 
Cardium tuberculatum is active on D,,, L,-CX-amino-S-hydroxycaproic acid 
according to the work of Glahn, Manchon, and Roche (14). The work of 
Meister (33) shows that the transamination reaction when catalyzed with 
Lactobacillus arabinosus extracts, is possible with hexahomoserine and 
w-N-chloroacetyl derivative of lysine, but not with free lysine. This 
indicates that the presence of a free ~-amino group inhibits transamina-
tiono Roche, Thoai and Verrier (43) noted varying amounts of inhibition 
on the reaction of purified arginase from beef liver on L-arginine when 
hexahomoserine was added. Formation of a cobalt-amino acid is thought to 
be responsible for this inhibition. Yura and Vogel (47, 48) found that 
cx-amino-adipic-S-semialdehyde is the product formed when hexahomoserine 
is used as the substrate for the dehydrogenation reaction catalyzed by 
w-hydroxy-cx-amino acid dehydrogenase. This reaction is DPN- or TPN-
dependent and only the L-isomer of hexahomoserine is active. The enzyme 
which catalyzes this reaction appears to be the same enzyme which cata-
lyzes the pyrroline-5-carboxylate reductase of Neurospora crassa. This 
probably accounts for the reason that hexahomoserine will satisfy the 
lysine requirement of certain Neurospora mutants. 
Hasse, Homann, and Schuhrer (18) show that the product of the 
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enzymic oxidation of hexahomoserine by a<.Joohydroxy-a-amino acid dehydro-
genase (from Neurospora crassa) after purification on Dowex 50 is ~ 1 -
piperideine-6-carboxylic acid. They found that this compound is also 
the product of the oxidation of lysine by diamine oxidase (from pea seed-
lings) at pH 6-10. 
Davis (5) found that 10 - 300 µgm/ml. of D,L-a-amino-c-hydroxycaproic 
acid does not inhibit or cause a response from the mutants 173-25, 173-
25c3, 26-26, 81-47, 81-83, 81-29, 81-43, 122-64, 39A-21 of Escherichia 
.£2.!i. Meadow, Hoare and Work (31) and Meadow and Work (32) found that 
hexahomoserine had no effect on lactobacilli or the lysine-requiring ]h_ 
coli mutants 173-25 and 26-26. It did not replace lysine for growth and 
did not prevent or cause lysis to occur. They found that it either in-
hibited growth or replaced lysine in Neurospora mutants. Ravel et al. 
(42) show that hexahomoserine does not replace lysine in Lactobacillus 
arabinosus or 1· casii. 
In studying hexahomoserine as a substitute for lysine for Neurospora, 
Good et al. (15) found that the mutants 33933 and 4545 could utilize the 
substance for growth. It was found that when mutant 4545 grown on a 
given amount of hexahomoserine were reisolated and incubated, their growth 
responses to hexahomoserine varied considerably. Mutants 37101, 15069 
and 39302 utilize lysine like rats and are inhibited by hexahomoserine. 
They propose the following sequence of substances and mutations: 
33933 4545 




r" '\ ,n lysine 
Schweet et al. (44) suggest the following metabolic scheme for lysine 
biosynthesis in Neurospora: 
a-amino 
' X ~~-' L-lysine adipic i 
acid 
E-hydroxynorleucine 
It is shown by Vogel (46) that the lysine pathway in Euglena is 
similar to the one in fungi (such as Candida and Neurospora). Using 
L-~14<j] aspartate as tracer and D1 L-hexahomoserine as the unlabeled 
supplement, he finds that the radioactivity in the protein lysine (but 





Hexahomoserine added to a complete basal ration or one containing 
no lysine produces anemia in rats. According to Mertz et al. (36)., in 
young white rats on a diet containing 2 per cent D.,L-lysine HCl., the 
addition of as little as 1 per cent D.,L-hexahomoserine will inhibit 
growth and produce symptoms of anemia. Page and Gingras (39) and Page; 
Gingras and Gaudry (41) showed that accompanying the anemia is a marked 
rise in the blood plasma amino nitrogen. In further studies Page., Gaudry 
and Gingras (38) and Mertz et al. (34) found that hemoglobin., red cell 
count and red cell volume are lowered. Other blood substances remain 
normal. Martel (24, 25) and Martel and Gingras (29) found that there is 
a rise in the blood amino acid without changing urinary excretion. Creat-
inine excretion increases., while creatine excretion decreases or ceases. 
The latter pair in further tests found that plasma and muscle creatinine 
are not altered. In a single study Gaudry (10) showed that plasma ablumin 
and globulins decrease markedly. A loss of weight always accompanies the 
anemia. In histological studies Gingras, Page and Gaudry (13) found that 
the kidneys increase in weight., but show no abnormalities. Page., Gingras 
and Gaudry (37) showed that lysine given simultaneously with hexahomoserine 
prevents the anemia and partially improves growth., but has no effect on 
the plasma amino nitrogen. 
According to Mertz and Golubow (35), when hexahomoserine is resolved 
12 
and the isomers fed to weanling rats, it is found that the D-isomer 
caused no significant reduction in the average red blood cell count and 
reduces the average weight gain to about one-fourth that of the controls. 
The L-isomer reduces the average red cell count to about one-third and 
the average weight gain to about one-half that of the controls. They 
concluded that the D-isomer acts as a specific growth depressant, while 
the L-isomer depresses both growth and red cell production. 
Gaudry and Martel (11) showed that when hexahomoserine is fed to 
rats, it is changed to a-keto acids by oxidative deamination and is 
almost completely discharged in the urine. In a later study Martel (26) 
showed that. in addition to the increase in urinary excretion of ketonic 
acids, there is also an increased excretion of pyruvic and oxoglutaric 
acids. DeLong (6) proposes that his data suggests that part of the amino 
acid is metabolized via a-keto-6-hydroxycaproic acid and part via a-keto-
caproic acid, indicating both an oxidative and nonoxidative pathway. 
The reduction in growth of Novikoff heptoma in rats when hexahomo-
serine is administered, as proven by Martel and Berlinquet (27) shows 
that hexahomoserine possesses chemotherapeutic properties on cancer. 
Martel and Gingras (28) showed that the addition of 1.5 per cent of hexa-
homoserine to the diet of rats prevents the polycythemia (high hemoglobin, 
number of red cells, and total cell volume) induced by the addition of 
0.1 per cent cobalt chloride to the ration. For these reasons Gaudry (10) 
proposes that hexahomoserine might be tried clinically in severe cases of 
polycythemia vera to try to control a high hemoglobin level, red cell count 
and cell volume. 
Bergeron and Bourbeau (2,3) studied the chronic toxicity of hexahomo-
serine for the dog. They found that hexahomoserine administered daily 
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in the diet of dogs produces hyprochromic, microcytic anemia, the severity 
depending upon the amount of hexahomoserine administered. Evidence, such 
as anorexia, loss in weight, muscular atropy, skin ulcers, and epilation, 
shows chronic intoxication by hexahomoserine. Taxi-infectious lesions 
with centrolobular degeneration and in a few cases a slight fatty metamor-
phosis were discovered by an autopsy on dogs which had died during the 
experimental period. There was a decrease in the index and mean diameter 
of the erythrocytes. There was no change in the blood chemistry. Sus-
ceptibility to infection increased among the dogs. In all cases the symp-
toms were reversible and 10 weeks after hexahomoserine was omitted from 
the diet, the dogs were normal. 
Athens, Cartwright and Wintrobe (1) fed a lysine-deficient diet with 
hexahomoserine to swine. The swine developed a normocytic, normochromic 
anemia which was accompanied by hypoalbuminemia and hypocupremia. There 
was no change in the plasma iron concentration or in bone marrow morphology. 
The data indicates that lysine is essential for normal erythropoiesis in 
swine. In other studies with swine Mertz et al. (34) showed that the red 
cell count is lowered, but all. other blood substances remain unchanged. 
Gaudry (10) proposes that hexahomoserine is possibly a lysine anta-
gonist in all mannnals. Acting as a competitive inhibitor to lysine, it 
prevents lysine's normal incorporation into protein molecules. The L-
isomer appears to be the active form. 
CHAPTER VI 
SUMMARY 
The chemical structure of hexahomoserine was proven when it was 
synthesized f:rom S-hydroxyvaleraldehyde. Later, by chromatographic 
methods hexahomoserine was proven to be the same compound as the anemia-
causing factor in deaminated casein. The active form is the L-isomer. 
It has been shown that hexahomoserine is a lysine antagonist in many 
organisms, preventing growth and causing anemia" Its probable mode of 
action is to act as a competitive inhibitor to lysine, preventing lysine's 
normal incorporation into protein molecules" Lysine administered simul-
taneously will promote growth without affecting the lowered red cell 
count caused by hexahomoserine. In many cases after hexahomoserine was 
removed from 'the diet and replaced with lysine, the animals returned to 
normal after a period of time" An interesting property of hexahomoserine 
is that it exhibits chemotherapeutic properties on cancer in rats. It 
also demonstrates properties which might make it a successful agent for 
treating polycythemia verao 
Other names found in the literature for hexahomoserine are a-amino-
E-hydroxycaproic acid, 2-amino-6-hydroxycaproic acid, a-amino-€-hydroxy-
hexanoic acid, ~-hydroxynorleucine and 6-hydroxynorleucine. 
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